Cite
HARVARD Citation
Yamazaki, K. et al. (n.d.). 2116 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). European journal of cancer. pp. S368-S369. [Online].